Multiple approved products, a national published price range, and an all-in course from ≈ $170,000 — against US full-treatment costs of $550,000–850,000.
CAR-T (chimeric antigen receptor T-cell) therapy is a personalized immunotherapy: your own T cells are collected, engineered in a lab to recognize a marker on cancer cells, multiplied, and infused back after a short course of conditioning chemotherapy. It is a single-course hospital treatment typically involving 2–4 weeks of inpatient monitoring, including management of possible side effects such as cytokine release syndrome (CRS).
China has one of the world's largest approved CAR-T markets, with multiple domestically developed products approved by the national regulator (NMPA) and in routine clinical use at major hospitals — including for multiple myeloma, large B-cell lymphoma, and B-cell acute lymphoblastic leukemia (B-ALL).
Hospital departments commonly evaluate CAR-T for:
BCMA-targeted products after prior lines of therapy — the most common adult indication in China.
Relapsed / refractory DLBCL and related subtypes after at least two prior lines.
Relapsed or refractory B-cell acute lymphoblastic leukemia — pediatric protocols available at dedicated children's hospitals.
Selected follicular lymphoma, MCL and CLL cases, reviewed case by case.
CAR-T pricing has two separate layers, and understanding both is the only way to read a realistic quote:
| Layer | China | Notes |
|---|---|---|
| 1 — The cell productthe engineered cells themselves | $137,000 – 179,000 | National list prices, published and identical for every patient — Chinese or international. There is no "foreigner price" on the drug itself. Currently five approved products across this range. |
| 2 — Hospital servicesconditioning chemo, 2–4 weeks monitored inpatient stay (often in a protected single room), labs, CRS management | ≈ $21,000 – 60,000 international-department pricing | Local-patient services run ≈ $14,000 – 42,000; international departments typically price 1.5–2× local rates. Severe CRS requiring ICU care increases this layer. |
| All-in typical range | from ≈ $170,000 typical band $150,000 – 230,000 | US full-treatment costs for approved CAR-T products are reported at ≈ $550,000 – 850,000, against drug list prices of $373,000 – 475,000 for the products alone. |
The strongest comparison is ciltacabtagene autoleucel (cilta-cel): a CAR-T product developed in China that is now also FDA-approved, and which was tested in pivotal trials in both countries. Same product, two geographies — the response rates are directly comparable.
| Trial & product | Published response rates | Details |
|---|---|---|
| CARTIFAN-1China pivotal trial — basis of the 2024 NMPA approval | Overall response 87.9% Complete response or better 79.3% | Heavily pretreated myeloma patients. Median follow-up 37 months; median progression-free survival 30 months (NCT03758417). |
| CARTITUDE-1US pivotal trial — same product, basis of the FDA approval | Overall response 98% About one third still progression-free at 5 years | Similar relapsed/refractory myeloma population (NCT03548207; 5-year follow-up reported at EHA 2025). |
You send diagnosis, treatment history and recent reports; we confirm which hospitals and products realistically fit.
Your case is presented to suitable hematology departments; you receive written quotes and plans before committing to anything.
Visa invitation letter, flights and accommodation near the hospital are arranged before you fly.
Leukapheresis (cell collection) is performed; manufacturing typically takes 2–4 weeks — some patients have bridging therapy during this window.
Short conditioning chemotherapy, then the cell infusion, followed by monitored inpatient care — usually in a protected single room — for 2–4 weeks.
Interpreter-supported discharge, English documents where the hospital provides them, and a follow-up plan — including medication refills on later trips.
Reference ranges for all treatments, side-by-side with US prices.
The other precision-oncology pathway we coordinate, $30,000–50,000 per course.
The six-step process from first inquiry to follow-up, with fee timing.
Then the free case review can start now — we will tell you what to send and what is realistically possible.